RecruitingNCT07673016
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Sponsor
Convergent Genomics, Inc.
Enrollment
2,500 participants
Start Date
Oct 15, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with bladder cancer, hematuria, and other related conditions. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07673016
Related Trials
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT0727741316 locations
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
NCT063945701 location
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT0741929571 locations
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT0617247885 locations
SL-28 for Advanced Solid Tumours
NCT073417371 location